Logo
x

Search

Subscribe Now

 EMA

GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer

GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer

  • December 19, 2024
Roche Reports the EMA’s Approval of Vabysmo Prefilled Syringe (PFS) for three Retinal Conditions Causing Blindness

Roche Reports the EMA’s Approval of Vabysmo Prefilled Syringe (PFS) for three Retinal Conditions Causing Blindness

  • December 13, 2024
New Drug Designations - October 2024

New Drug Designations - October 2024

  • November 26, 2024
Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

  • November 21, 2024
Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

  • October 30, 2024
New Drug Designations - September 2024

New Drug Designations - September 2024

  • October 29, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.